Cargando…

Application of Neurokinin-1 Receptor in Targeted Strategies for Glioma Treatment. Part I: Synthesis and Evaluation of Substance P Fragments Labeled with (99m)Tc and (177)Lu as Potential Receptor Radiopharmaceuticals

Gliomas, particularly WHO grade IV glioblastoma multiforme, are one of the most common and aggressive primary tumors of the central nervous system. The neuropeptide, substance P (SP), is the physiological ligand of the neurokinin-1 (NK-1) receptor that is consistently overexpressed in glioblastoma c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Majkowska-Pilip, Agnieszka, Koźmiński, Przemysław, Wawrzynowska, Anna, Budlewski, Tadeusz, Kostkiewicz, Bogusław, Gniazdowska, Ewa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222600/ https://www.ncbi.nlm.nih.gov/pubmed/30301182 http://dx.doi.org/10.3390/molecules23102542

Ejemplares similares

Common Shortcomings in Study on Radiopharmaceutical Design Research: A Case Study of (99m)Tc-Labelled Methotrexate
por: Koźmiński, Przemysław, et al.
Publicado: (2021)

Physicochemical and Biological Study of (99m)Tc and (68)Ga Radiolabelled Ciprofloxacin and Evaluation of [(99m)Tc]Tc-CIP as Potential Diagnostic Radiopharmaceutical for Diabetic Foot Syndrome Imaging
por: Koźmiński, Przemysław, et al.
Publicado: (2021)

In Vitro Biological Evaluation of Aprepitant Based (177)Lu-Radioconjugates
por: Halik, Paweł K., et al.
Publicado: (2022)

Developments in (177)Lu-based radiopharmaceutical therapy and dosimetry
por: George, Siju C., et al.
Publicado: (2023)

Evaluation of the (177m)Lu-concentration in in-house produced (177)Lu-radiopharmaceuticals and commercially available Lutathera(®)
por: Balzer, Matthias, et al.
Publicado: (2023)

Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors
por: Halik, Paweł K., et al.
Publicado: (2020)

The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy
por: Majkowska-Pilip, Agnieszka, et al.
Publicado: (2019)

Novel NK1R-Targeted (68)Ga-/(177)Lu-Radioconjugates with Potential Application against Glioblastoma Multiforme: Preliminary Exploration of Structure–Activity Relationships
por: Matalińska, Joanna, et al.
Publicado: (2022)

The impact of (177)Lu-octreotide therapy on (99m)Tc-MAG3 clearance is not predictive for late nephropathy
por: Werner, Rudolf A., et al.
Publicado: (2016)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on (99m)Tc-Octreotide and posttherapeutic (177)Lu-DOTA-TATE scans
por: Amoui, Mahasti, et al.
Publicado: (2021)

Toxicity Assessment of [(177)Lu]Lu−iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes
por: Hernández-Jiménez, Tania, et al.
Publicado: (2022)

In Vitro Evaluation of Tc-99m Radiopharmaceuticals for Gastric Emptying Studies
por: Ertay, Türkan, et al.
Publicado: (2014)

Influence of Storage Temperature on Radiochemical Purity of (99m)Tc-Radiopharmaceuticals
por: Uccelli, Licia, et al.
Publicado: (2018)

Lipidic Cubic-Phase Nanoparticles (Cubosomes) Loaded with Doxorubicin and Labeled with (177)Lu as a Potential Tool for Combined Chemo and Internal Radiotherapy for Cancers
por: Cytryniak, Adrianna, et al.
Publicado: (2020)

Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
por: Rumiantcev, Mikhail, et al.
Publicado: (2023)

Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy
por: Rusckowski, Mary, et al.
Publicado: (2016)

Impact of radiopharmaceutical therapy ((177)Lu, (225)Ac) microdistribution in a cancer-associated fibroblasts model
por: Tranel, Jonathan, et al.
Publicado: (2022)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Doxorubicin- and Trastuzumab-Modified Gold Nanoparticles as Potential Multimodal Agents for Targeted Therapy of HER2+ Cancers
por: Żelechowska-Matysiak, Kinga, et al.
Publicado: (2023)

Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [(177)Lu]Lu-PSMA
por: Hooijman, Eline L., et al.
Publicado: (2022)

Impact of the dead-time correction method on quantitative (177)Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy
por: Desy, Alessandro, et al.
Publicado: (2022)

Radiolysis-Associated Decrease in Radiochemical Purity of (177)Lu-Radiopharmaceuticals and Comparison of the Effectiveness of Selected Quenchers against This Process
por: Larenkov, Anton, et al.
Publicado: (2023)

Synthesis and Ready to Use Kit Formulation of EDTMP for the Preparation of 177Lu-EDTMP as a Bone Palliation Radiopharmaceutical
por: Mercanoglu, Guldem, et al.
Publicado: (2023)

Comparison of the Absorbed Dose for (99m)Tc-Diethylenetriaminepentaacetic Acid and (99m)Tc-Ethylenedicysteine Radiopharmaceuticals using Medical Internal Radiation Dosimetry
por: Pirdamooie, Shokufeh, et al.
Publicado: (2015)

Improvement of the Effectiveness of HER2+ Cancer Therapy by Use of Doxorubicin and Trastuzumab Modified Radioactive Gold Nanoparticles
por: Żelechowska-Matysiak, Kinga, et al.
Publicado: (2023)

Mathematical Simulation of Transport Kinetics of Tumor-Imaging Radiopharmaceutical (99m)Tc-MIBI
por: Shevtsova, O. N., et al.
Publicado: (2017)

Accuracy of two dosimetry software programs for (177)Lu radiopharmaceutical therapy using voxel-based patient-specific phantoms
por: Ramonaheng, Keamogetswe, et al.
Publicado: (2022)

Recombinant Complement Receptor 2 Radiolabeled with [(99m)Tc(CO)(3)](+) : A Potential New Radiopharmaceutical for Imaging Activated Complement
por: Badar, Adam, et al.
Publicado: (2011)

Alternative chromatographic system for the quality control of lipophilic technetium-99m radiopharmaceuticals such as [(99m)Tc(MIBI)(6)](+)
por: Faria, D.P., et al.
Publicado: (2015)

Feasibility of simplifying renal dosimetry in (177)Lu peptide receptor radionuclide therapy
por: Sundlöv, Anna, et al.
Publicado: (2018)

Radiopharmaceutical supply disruptions and the use of (99m)Tc-hydroxymethylene diphosphonate as an alternative to (99m)Tc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement
por: Miller, Edward J., et al.
Publicado: (2022)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [(177)Lu]Lu-Satoreotide Tetraxetan and the Agonist [(177)Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST(2)-Positive Tumours
por: Plas, Pascale, et al.
Publicado: (2022)

Radiation Levels from Toilets Used By Patients Injected with 99mTc-based Radiopharmaceuticals in Ibadan
por: Ejeh, John Enyi, et al.
Publicado: (2014)

Sorbitol as a Polar Pharmacological Modifier to Enhance the Hydrophilicity of (99m)Tc-Tricarbonyl-Based Radiopharmaceuticals
por: Giammei, Carolina, et al.
Publicado: (2020)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vj4fh6ne4u2hd7br4qiqv4dkud